Updated packaging now available for SANDIMMUNE® 100 mg blister packages
Packaging of SANDIMMUNE® (cyclosporine capsules, USP) 100 mg soft gelatin capsules 30-count blister packs updated to meet federal child-resistant packaging requirements
Update implemented in cooperation with the US Consumer Product Safety Commission (CPSC) as part of previously announced CPSC-approved corrective action plan that concerned packaging only
Novartis Pharmaceuticals Corporation (Novartis) announced new packaging is now available for 30-count blister card packages (blister packs) of SANDIMMUNE® (cyclosporine capsules, USP) 100 mg soft gelatin capsules. The updated packaging was implemented in cooperation with the US Consumer Product Safety Commission (CPSC) to ensure it meets federal child-resistant packaging requirements, as part of a previously announced CPSC-approved corrective action plan for SANDIMMUNE 100 mg soft gelatin capsules 30-count blister packs distributed in the US.
There were no quality or efficacy issues with the medicine for its intended use; the action concerned packaging only. Novartis takes its responsibility for consumer safety very seriously and made the following package design changes to ensure the blister packs of SANDIMMUNE 100 mg soft gelatin capsules meet federal child-resistant packaging requirements.
Foil thickness increased to improve the toughness, puncture-resistance, and peel-strength properties of the blister packs.
Blister card size increased to incorporate a larger seal area.
Secondary packaging (folding carton) enlarged to fit the larger blister cards inside.
Blister perforations removed to eliminate the potential of a child peeling back the blister from the perforation.
Circular thumb-notch cut-outs removed from the blister cards to increase the difficulty of a child penetrating the blister card at these locations.
Scissor icon and dotted line added to the blister card artwork to direct the (adult) patient to cut the foil open along this line to remove the capsule.
Patient directions for using the blister card updated on the folding carton box artwork, based on the package design changes.
As soon as the company became aware that these blister packs posed a potential risk of harm if children opened the package and swallowed the medicine, Novartis promptly notified the CPSC and the US Food and Drug Administration (FDA) and has been working closely with the CPSC to remedy the packaging and ensure continuity of treatment.
Patients should ask their healthcare professional if they have questions about the new packaging. Healthcare professionals with questions should contact Novartis Medical Information at 1-888-669-6682.
The previously announced CPSC-approved corrective action plan included production lots of SANDIMMUNE 100 mg 30-count blister packs and liquid filled single capsule blister packs, and NEORAL® (cyclosporine capsules, USP) MODIFIED 100 mg soft gelatin capsules 30-count blister packs, within expiry distributed in the US. Information on this corrective action, and affected lot numbers and NDC with expiry dates and package photos, are available at: https://www.novartis.us/news/statements/corrective-action-certain-100-mg-sandimmune-and-neoral-blister-packages-us. SANDIMMMUNE (cyclosporine capsules, USP) 25 mg soft gelatin capsules and NEORAL (cyclosporine capsules, USP) MODIFIED 25-mg soft gelatin capsules 30-count packages were not included in the corrective action, nor were SANDIMMUNE oral solution in bottles and SANDIMMUNE concentrate for infusion in ampules.
An update on new packaging for 30-count blister packs of NEORAL 100 mg soft gelatin capsules will be shared once it is available. Patients who still have SANDIMMUNE 100 mg soft gelatin capsules or NEORAL MODIFIED 100-mg soft gelatin capsules affected by this action in their possession can request a free child-resistant pouch by calling toll free 1-866-629-6182 between the hours of 8 a.m.-8 p.m. ET or by sending an email to [email protected].
Disclaimer This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.